FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895588108> ?p ?o ?g. }

• W2895588108 abstract "Background New, minimally invasive surgeries have emerged as alternatives to transurethral resection of the prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Aquablation is a novel, minimally invasive, water‐based therapy, combining image guidance and robotics for the removal of prostatic tissue. Objectives To assess the effects of Aquablation for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Search methods We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to 11 February 2019, with no restrictions on the language or status of publication. Selection criteria We included parallel‐group randomised controlled trials (RCTs) and cluster‐RCTs, as well as non‐randomised observational prospective studies with concurrent comparison groups in which participants with BPH who underwent Aquablation. Data collection and analysis Two review authors independently assessed studies for inclusion at each stage, and undertook data extraction and 'Risk of bias' and GRADE assessments of the certainty of the evidence. We considered review outcomes measured up to and including 12 months after randomisation as short‐term and beyond 12 months as long‐term. Main results We included one RCT with 184 participants comparing Aquablation to TURP. The mean age and International Prostate Symptom Score were 65.9 years and 22.6, respectively. The mean prostate volume was 53.2 mL. We only found short‐term data for all outcomes based on a single randomised trial. Primary outcomes Up to 12 months, Aquablation likely results in a similar improvement in urologic symptom scores to TURP (mean difference (MD) −0.06, 95% confidence interval (CI) −2.51 to 2.39; participants = 174; moderate‐certainty evidence). We downgraded the evidence certainty by one level due to study limitations. Aquablation may also result in similar quality of life when compared to TURP (MD 0.27, 95% CI −0.24 to 0.78; participants = 174, low‐certainty evidence). We downgraded the evidence certainty by two levels due to study limitations and imprecision. Aquablation may result in little to no difference in major adverse events (risk ratio (RR) 0.84, 95% CI 0.31 to 2.26; participants = 181, very low‐certainty evidence) but we are very uncertain of this finding. This would correspond to 15 fewer major adverse events per 1000 participants (95% CI 64 fewer to 116 more). We downgraded the evidence certainty by one level for study limitations and two levels for imprecision. Secondary outcomes Up to 12 months, Aquablation may result in little to no difference in retreatments (RR 1.68, 95% CI 0.18 to 15.83; participants = 181, very low‐certainty evidence) but we are very uncertain of this finding. This would correspond to 10 more retreatments per 1000 participants (95% CI 13 fewer to 228 more). We downgraded the evidence certainty by one level due to study limitations and two levels for imprecision. Aquablation may result in little to no difference in erectile function as measured by International Index of Erectile Function questionnaire Erectile Function domain compared to TURP (MD 2.31, 95% CI −0.63 to 5.25; participants = 64, very low‐certainty evidence), and may cause slightly less ejaculatory dysfunction than TURP, as measured by Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MD 2.57, 95% CI 0.60 to 4.53; participants = 121, very low‐certainty evidence). However, we are very uncertain of both findings. We downgraded the evidence certainty by two levels due to study limitations and one level for imprecision for both outcomes. We did not find other prospective, comparative studies comparing Aquablation to TURP or other procedures such as laser ablation, enucleation, or other minimally invasive therapies. Authors' conclusions Based on short‐term (up to 12 months) follow‐up, the effect of Aquablation on urological symptoms is probably similar to that of TURP (moderate‐certainty evidence). The effect on quality of life may also be similar (low‐certainty evidence). We are very uncertain whether patients undergoing Aquablation are at higher or lower risk for major adverse events (very low‐certainty evidence). We are very uncertain whether Aquablation may result in little to no difference in erectile function but offer a small improvement in preservation of ejaculatory function (both very low‐certainty evidence). These conclusions are based on a single study of men with a prostate volume up to 80 mL in size. Longer‐term data and comparisons with other modalities appear critical to a more thorough assessment of the role of Aquablation for the treatment of LUTS in men with BPH." @default.
• W2895588108 created "2018-10-12" @default.
• W2895588108 creator A5001861927 @default.
• W2895588108 creator A5014757964 @default.
• W2895588108 creator A5030743787 @default.
• W2895588108 creator A5036514742 @default.
• W2895588108 creator A5071905039 @default.
• W2895588108 date "2019-02-13" @default.
• W2895588108 modified "2023-09-27" @default.
• W2895588108 title "Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia" @default.
• W2895588108 cites W1491256997 @default.
• W2895588108 cites W1523669219 @default.
• W2895588108 cites W1583848026 @default.
• W2895588108 cites W1890512450 @default.
• W2895588108 cites W1935314716 @default.
• W2895588108 cites W1943830934 @default.
• W2895588108 cites W1973789421 @default.
• W2895588108 cites W1979837745 @default.
• W2895588108 cites W1985085981 @default.
• W2895588108 cites W2001432092 @default.
• W2895588108 cites W2002004951 @default.
• W2895588108 cites W2005687876 @default.
• W2895588108 cites W2009567938 @default.
• W2895588108 cites W2021505568 @default.
• W2895588108 cites W2037171825 @default.
• W2895588108 cites W2050675379 @default.
• W2895588108 cites W2053766817 @default.
• W2895588108 cites W2068706053 @default.
• W2895588108 cites W2086240335 @default.
• W2895588108 cites W2090132603 @default.
• W2895588108 cites W2092630235 @default.
• W2895588108 cites W2096998881 @default.
• W2895588108 cites W2099286969 @default.
• W2895588108 cites W2104675861 @default.
• W2895588108 cites W2106455438 @default.
• W2895588108 cites W2125435699 @default.
• W2895588108 cites W2126629865 @default.
• W2895588108 cites W2126930838 @default.
• W2895588108 cites W2132697170 @default.
• W2895588108 cites W2134236426 @default.
• W2895588108 cites W2142269413 @default.
• W2895588108 cites W2149824633 @default.
• W2895588108 cites W2153655221 @default.
• W2895588108 cites W2154659002 @default.
• W2895588108 cites W2161227160 @default.
• W2895588108 cites W2164636380 @default.
• W2895588108 cites W2483800985 @default.
• W2895588108 cites W2579618791 @default.
• W2895588108 cites W2729937958 @default.
• W2895588108 cites W2737405214 @default.
• W2895588108 cites W2765277689 @default.
• W2895588108 cites W2770733749 @default.
• W2895588108 cites W2784615683 @default.
• W2895588108 cites W2789340182 @default.
• W2895588108 cites W2790828175 @default.
• W2895588108 cites W2802619689 @default.
• W2895588108 cites W2803752334 @default.
• W2895588108 cites W2803890867 @default.
• W2895588108 cites W2883261765 @default.
• W2895588108 cites W3022903699 @default.
• W2895588108 cites W3023552461 @default.
• W2895588108 cites W3109514050 @default.
• W2895588108 cites W4233653137 @default.
• W2895588108 cites W4238372968 @default.
• W2895588108 cites W4242295386 @default.
• W2895588108 cites W4246953332 @default.
• W2895588108 cites W4256004275 @default.
• W2895588108 doi "https://doi.org/10.1002/14651858.cd013143.pub2" @default.
• W2895588108 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6373984" @default.
• W2895588108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30759311" @default.
• W2895588108 hasPublicationYear "2019" @default.
• W2895588108 type Work @default.
• W2895588108 sameAs 2895588108 @default.
• W2895588108 citedByCount "11" @default.
• W2895588108 countsByYear W28955881082020 @default.
• W2895588108 countsByYear W28955881082021 @default.
• W2895588108 countsByYear W28955881082022 @default.
• W2895588108 countsByYear W28955881082023 @default.
• W2895588108 crossrefType "journal-article" @default.
• W2895588108 hasAuthorship W2895588108A5001861927 @default.
• W2895588108 hasAuthorship W2895588108A5014757964 @default.
• W2895588108 hasAuthorship W2895588108A5030743787 @default.
• W2895588108 hasAuthorship W2895588108A5036514742 @default.
• W2895588108 hasAuthorship W2895588108A5071905039 @default.
• W2895588108 hasBestOaLocation W28955881082 @default.
• W2895588108 hasConcept C121608353 @default.
• W2895588108 hasConcept C126322002 @default.
• W2895588108 hasConcept C126894567 @default.
• W2895588108 hasConcept C168563851 @default.
• W2895588108 hasConcept C17744445 @default.
• W2895588108 hasConcept C199539241 @default.
• W2895588108 hasConcept C23131810 @default.
• W2895588108 hasConcept C2776235491 @default.
• W2895588108 hasConcept C2776478404 @default.
• W2895588108 hasConcept C2776547966 @default.
• W2895588108 hasConcept C2777562237 @default.
• W2895588108 hasConcept C2779473830 @default.
• W2895588108 hasConcept C2779478474 @default.
• W2895588108 hasConcept C2780768273 @default.
• W2895588108 hasConcept C29456083 @default.

• next